Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 334.50
Bid: 331.50
Ask: 333.00
Change: 0.00 (0.00%)
Spread: 1.50 (0.452%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 334.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

Fri, 06th Aug 2021 10:55

(Alliance News) - ReNeuron Group PLC on Friday said it has hired Catherine Isted, a finance professional and chartered accountant, as chief financial officer.

Bridgend, Wales-based ReNeuron is a biotechnology company focused on the development of novel stem cell therapies.

ReNeuron noted that Isted has 23 years of experience in the healthcare industry, including 12 years as a partner in two leading healthcare banking teams. She replaces Michael Hunt, who resigned in March after 20 years at the company

Isted "has an excellent knowledge of the healthcare sector and is highly skilled in equity capital markets, [mergers and acquisitions] and strategic business development," said Chair Ian Ross.

Isted joins ReNeuron from cell and gene therapy firm Oxford Biomedica PLC, where she was a member of the finance leadership team heading up Corporate Development and Investor Relations.

Formerly, Isted held research analyst and equity sales positions in the healthcare teams at New York-based investment bank Morgan Stanley, Dutch lender ABN AMRO Bank NV, Tokyo-based financial services provider Nomura Holdings Inc, and London-based stockbroker and investment bank Peel Hunt LLP.

Shares in ReNeuron were trading up 9.4% at 109.00 pence each in London on Friday morning. Oxford BioMedica shares were down 1.5% at 1,352.97p.

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Aug 2022 14:30

EXECUTIVE CHANGES: ReNeuron promotes CFO Catherine Isted to CEO role

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:

Read more
26 Jul 2022 11:12

SMALL-CAP WINNERS & LOSERS: Reach and Wickes sink on dark outlook

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.

Read more
26 Jul 2022 11:09

Oxford BioMedica begins new project and signs license agreement

(Alliance News) - Oxford BioMedica PLC on Tuesday said it started a new project and signed a license and supply agreement.

Read more
26 Jul 2022 08:44

Oxford Biomedica inks LSA with US biotech firm, launches new project with Orchard Therapeutics

(Sharecast News) - Gene and cell therapy group Oxford Biomedica inked a new licence and supply agreement with an unnamed US private biotechnology on Tuesday company and also launched a new project with Orchard Therapeutics.

Read more
22 Jul 2022 10:36

SMALL-CAP WINNERS & LOSERS: Made.com and Hochschild slide again

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
21 Jul 2022 11:13

IN BRIEF: Oxford BioMedica shares up on deal expansion in CAR-T

Oxford BioMedica PLC - Oxford, England-based gene and cell therapy company - Expands its license and clinical supply agreement with Juno Therapeutics Inc, subsidiary of New-York based pharmaceutical industry company Bristol Myers Squibb. It says the expansion relates to the start of two new viral vector programmes for CAR-T therapies. "Oxford Biomedica will receive an undisclosed target nomination fee and potential payments upon the achievement of certain milestones," it notes.

Read more
21 Jul 2022 10:28

SMALL-CAP WINNERS & LOSERS: Go-Ahead suitor pulls out; Costain rises

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

Read more
1 Jul 2022 10:41

SMALL-CAP WINNERS & LOSERS: Oxford BioMedica rises on AstraZeneca deal

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
1 Jul 2022 08:56

LONDON MARKET OPEN: Recession fear hits stocks; Oxford Biomedica rises

(Alliance News) - Stocks in London opened lower on Friday as investors continued to fret over prospects of a recession as central banks raise interest rates.

Read more
1 Jul 2022 08:31

Oxford BioMedica signs new Covid-19 vaccine deal with AstraZeneca

(Alliance News) - Oxford BioMedica PLC on Friday said it has signed a new three year agreement with AstraZeneca PLC, which will facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine.

Read more
1 Jul 2022 08:07

LONDON BRIEFING: Oxford Biomedica signs new Covid jab deal with Astra

(Alliance News) - Oxford Biomedica on Friday said that it has signed a new three-year agreement with AstraZeneca, which would facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine.

Read more
1 Jul 2022 07:48

LONDON MARKET PRE-OPEN: Oxford Biomedica inks new AstraZeneca jab deal

(Alliance News) - Stock prices in London are seen opening lower on Friday following another sell-off on Wall Street fuelled by recession fears, while focus will be on a slew of manufacturing PMI readings later in the day.

Read more
1 Jul 2022 07:03

Oxford Biomedica signs new Covid vaccine deal with AstraZeneca

(Sharecast News) - Oxford Biomedica has signed a new three-year deal to make AstraZeneca's Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.

Read more
14 Jun 2022 11:16

US FDA lifts clinical hold on Oxford BioMedica partner's trial

(Alliance News) - Oxford BioMedica PLC on Tuesday noted that the US Food & Drug Administration lifted the clinical hold on Homology Medicines Inc's pheNIX gene therapy trial.

Read more
14 Jun 2022 09:35

Oxford Biomedica sees FDA lift clinical hold on Homology's HMI-102 trial

(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Tuesday that the US Food and Drug Administration had notified Homology Medicines that the clinical hold on its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria had been lifted.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.